The dysregulation of these oncogenes drives B-cell hematological malignancies such as follicular lymphoma (BCL2 translocation, MLL2 inactivation) (11, 67) DLBCL (e.g. BCL6, BCL2 and MYC translocation) (8, 68, 69) or Burkitt’s lymphoma (MYC translocation) (70, 71). Here, BCL2 is linked to Burkitt lymphoma.